A-337 / Yifan Pharma, ITabMed 
Welcome,         Profile    Billing    Logout  

1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
A-337 / ITabMed
A-337, NCT06093698: An Exploratory Study of in the Management of Malignant Solid Dose Escalation and Expansion Phases

Not yet recruiting
1
94
NA
Recombinant Anti-EpCAM-CD3 Antibody Injection
ITabMed Co., Ltd.
Recurrent or Metastatic Solid Tumors
06/26
12/26

Download Options